This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00725296?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
